Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Gelteq Appoints Seasoned Pharma and Tech Executive, James Pekarsky, as Chief Financial Officer | ||
By: GlobeNewswire - 22 Jul 2021 | Back to overview list |
|
MELBOURNE, Australia, July 22, 2021 (GLOBE NEWSWIRE) -- Gelteq Pty Ltd, a global leader in ingestible gel technology for healthcare, nutrition and sports, has appointed James Pekarsky as chief financial officer, effective July 4, as the company accelerates its global launch, including its first major entry into the U.S. market. Pekarsky brings to Gelteq more than 30 years of finance and executive experience at biotech and technology companies. This includes 15 years as CEO and CFO for publicly listed companies, five years as general manager for large U.S.-based companies in Europe, and 10 years of start-up company experience in Silicon Valley leading several financings, IPOs, acquisitions and exits. Pekarsky earlier co-founded and served as CEO of BioPharmX, a NYSE-listed company focused on novel medication delivery systems, where he led several financings and its IPO. Since BioPharmX, he has served as an executive consultant for private companies in the medical and high-tech fields, advising on all facets of finance and operations, including fund raising, M&A, business development and corporate governance. “We welcome Jim’s extensive financial knowledge and operational experience, particularly his success with developing novel pharma delivery systems,” stated Simon Szewach, Gelteq co-founder and executive chairman. “His proven capabilities and knowhow greatly complement our fast-track for growth and our expanding team of industry pioneers. We expect Jim to play an essential role as we continue to ramp our sales and marketing, manufacturing and licensing programs on a global scale, as well as pursue opportunities in the capital markets to accelerate this growth.” Before co-founding BioPharmX, Pekarsky had served as CFO of a number of successful companies in the semiconductor industry, including Wavesat (acquired by Cavium Networks/Marvell), SiliconBlue Technologies (acquired by Lattice), Mosys (a Nasdaq-listed company), AccelChip (acquired by Xilinx) and Virage Logic Corporation (acquired by Synopsis). He also led the Nasdaq IPO of Virage. “I see tremendous market opportunities and multiple ways for Gelteq to capitalize on its extensive IP portfolio and growing number of international patents that support its innovative gel delivery system,” commented Pekarsky. “The sports, health and wellness, and pharma partnerships the company has formed are impressive and support its commercial rollout. I’m looking forward to supporting the company’s continued growth and international expansion.” Pekarsky received his Bachelor of Science in accounting from the Indiana University of Pennsylvania and MBA from Golden Gate University, San Francisco. About Gelteq Important Caution Regarding Forward Looking Statements Company Contact: Investor Relations Contact: |
||
|
||
Copyright 2021 GlobeNewswire | Back to overview list |